Trial reportRMD open2025
Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting.
Trial report in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the prevalence of poor health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE) in Lupus Low Disease Activity State (LLDAS) or Definitions of Remission in SLE (DORIS) remission and sustained LLDAS or sustained DORIS remission, after a 52-week therapeutic intervention.
methodsWe analysed data from four phase III trials of belimumab in SLE (BLISS-52, BLISS-76, BLISS-SC, EMBRACE; n=2406). Sustained LLDAS/remission was defined as persistent LLDAS/remission for at least two visits, maintained through week 52. Poor HRQoL was defined as Short Form-36 (SF-36) physical/mental component summary (PCS/MCS) and domain scores ≤the normative fifth percentile, Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scores <30 and responses of 'some/moderate problems' or 'extreme/major problems' in any of the five dimensions of the three-level version of EuroQol 5-Dimension (EQ-5D) health questionnaire.
resultsAt week 52, among patients in LLDAS, remission, sustained LLDAS and sustained remission, 15.7%, 13.6%, 14.3% and 9.0% reported poor SF-36 PCS, and 12.5%, 11.4%, 12.9% and 14.0% reported poor SF-36 MCS scores, respectively. The highest frequencies were reported in the physical functioning domain (24.0%-26.3%), while 18.5%-26.2% reported FACIT-F scores 30. Among EQ-5D dimensions, pain/discomfort yielded the greatest frequencies of poor HRQoL experience (27.9%-28.7%). While significant improvements were observed among patients achieving the treatment goals in all HRQoL outcomes over the 52-week study period, PCS scores remained below population norms.
conclusionsDespite LLDAS or DORIS remission, notable proportions of SLE patients report poor HRQoL, indicating that current therapeutic goal definitions do not fully capture patients' perspectives of health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.